CytRx,
a biopharmaceutical research and development company specializing in oncology
treatments, reported today it will be at the Oppenheimer 24th annual Healthcare
Conference, being held next week in New York City. The conference is being held
Tuesday, December 10 through Wednesday, December 11, 2013, at the Crowne Plaza
Hotel. The company’s President and CEO, Steven A. Kriegsman, and Executive Vice
President and Chief Medical Officer, Dr. Daniel Levitt, will be providing a
corporate update on Wednesday, December 11, 2013 at 4:30 PM EST.
The
presentation will be webcast, available at:
http://www.cytrx.com/investors/presentations
The
Oppenheimer conference is an event in which management teams from over 100
companies present up-to-date information on their companies and their
performances. Presenters cover a wide range of public and private healthcare
companies spanning over all of the healthcare industry, including: bio &
specialty pharmaceuticals; biotechnology; medical devices; healthcare
facilities; life science tools and diagnostics; healthcare information
technology and distribution, and healthcare providers and servicers.
CytRx’s
oncology pipeline is currently focused on the clinical development of
aldoxorubicin, its improved version of the widely-used chemotherapeutic
treatment doxorubicin.
Information
about CytRx’s Aldoxorubicin Clinical Trial Progress
CytRx
is conducting a global Phase 2b clinical trial with aldoxorubicin as a
treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial
primarily in the same indication and a Phase 1b study of aldoxorubicin in
combination with doxorubicin in patients with advanced solid tumors, and has
completed a Phase 1b pharmacokinetics clinical trial in patients with
metastatic solid tumors. CytRx plans to initiate under a special protocol
assessment a potential pivotal Phase 3 global trial with aldoxorubicin as a
therapy for patients with soft tissue sarcomas whose tumors have progressed
following treatment with chemotherapy. CytRx also has initiated a Phase 2
clinical trial with aldoxorubicin in patients with late-stage glioblastoma
(brain cancer) and plans to initiate a Phase 2 clinical trial for AIDS-related
Kaposi’s sarcoma.
Positive
Notes
In
an article on StreetInsider.com, analyst Ram Selvaraju noted CytRx’s positive
indicators as a stock buy, saying, “Over the course of the past several weeks,
CytRx has reported several significant developments. The firm previously
reported positive response data from a Phase 2b trial assessing aldoxorubicin
versus doxorubicin as front-line therapy in soft tissue sarcoma (STS).”
The
full article can be accessed at:
http://www.streetinsider.com/Analyst+Comments/Positive+Indicators+Ahead+for+CytRx+%28CYTR%29,+Aegis+Maintains+Buy/8921448.html
For
more information on CytRx, visit: www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
